Erin Quirk's Insider Trades & SAST Disclosures

Erin Quirk's most recent trade in Terns Pharmaceuticals Inc was a trade of 150,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Jan. 23, 2024.

Stock Client Name Client Category Action Reported to Exchange Quantity Post Transaction Holding Traded % Avg. Price Value Security Type
Terns Pharmaceuticals Inc
Erin Quirk President, Head of R&D 23 Jan 2024 150,000 150,000 - - Stock Option (Right to Buy)
Terns Pharmaceuticals Inc
Quirk Erin President, Head of R&D 23 Jan 2024 75,000 75,000 - 0 Common Stock
Terns Pharmaceuticals Inc
Erin Quirk President, Head of R&D 01 Feb 2023 600,000 600,000 - - Stock Option (Right to Buy)
Terns Pharmaceuticals Inc
Erin Quirk President and CMO 28 Sep 2021 142,500 142,500 - - Stock Option (Right to Buy)
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc  
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges
View All The Insider Trades